Delivering Artificial Intelligence-driven Self Care Solutions to Evaluate and Treat Skin Conditions

Johnson & Johnson Innovation, Asia Pacific, recently announced that it has facilitated a research collaboration between Johnson & Johnson Consumer Health and Hangzhou Yongliu Tech (Yongliu), a China-based startup company, to deliver a digital platform solution that will provide consumers with the ability to manage their fungal infections.

The digital solution is intended to be used by consumers to self-evaluate their fungal infections with an image-based artificial intelligence (AI) screening tool, leverage educational modules to better understand the basic cause of fungal infections, and more proactively manage the treatment of their hand and/or foot fungal infections.

Since early 2020, Yongliu has been able to develop and market digital solutions for skin diseases focused on psoriasis, atopic dermatitis (AD) and lupus erythematosus (LE). Currently, over 10,000 China-based dermatologists are registered on Yongliu’s platform and have collaborations with top tier public hospitals in China such as Peking Union Medical College Hospital, Shanghai Ruijin Hospital and more, demonstrating its value to dermatologists and patients.

Under the agreement, Johnson & Johnson Consumer Health will bring insights from a team of self care experts on fungal infection to further develop the fungal infection digital management solution, followed by the implementation of a controlled commercial study with up to 10,000 users. This collaboration underscores Johnson & Johnson Innovation’s commitment to enhance overall health outcomes for consumers through new and engaging digital therapeutics.

If you are working on early-stage research, solutions or technologies in consumer health or any of our cross-sector focus areas, submit your request below for a chance to discuss with the team!

https://jji.jnj/apac

Barcode
image

 

Cautions Concerning Forward-Looking Statements

This announcement contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Consumer Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Consumer Inc. and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.